趋化因子CCL20及其受体CCR6在乳腺癌患者外周血中的表达及意义  

Expression of chemokine CCL20 and its receptor CCR6 in peripheral blood from patients with breast cancer and its significance

作　　者：郭满盈[1] 王栋[2] 王伟明[3] 罗媛烨[1] 陈扬[3] 

机构地区：[1]解放军第98医院检验科,浙江湖州313000 [2]第二军医大学解剖学教研室,上海200433 [3]解放军第98医院院部,浙江湖州313000

出　　处：《检验医学》2011年第10期683-685,共3页Laboratory Medicine

基　　金：南京军区科技创新课题资助项目(09MA010)

摘　　要：目的研究乳腺癌患者外周血中趋化因子CCL20及其受体CCR6的表达变化在乳腺癌发病机制中的作用。方法把乳腺癌患者分为2组,癌组织上有CCR6表达的为CCR6+组,癌组织上未见有CCR6表达的为CCR6-组。采用酶联免疫吸咐试验(ELISA)检测乳腺癌患者及正常人血清中CCL20水平,同时用流式细胞仪分析外周血CD3+T淋巴细胞表面CCR6的表达。结果 CCR6+组患者血清CCL20水平明显高于正常对照组和CCR6-组(P均<0.01),各组外周血CD3+T淋巴细胞表面CCR6的表达差异无统计学意义。结论 CCR6+组患者血清CCL20水平升高可能在部分乳腺癌的发病过程中发挥作用。Objective To study the role of peripheral blood chemokine CCL20 and its receptor CCR6 in the pathogenesis of breast cancer.Methods The patients with breast cancer were classified into 2 groups,according to the expression of CCR6 in breast cancer tissue.One was with positive CCR6 expression（CCR6＋ patients）,and another was without CCR6 expression（CCR6-patients）.The serum levels of CCL20 were determined by enzyme-linked immunosorbent assay（ELISA） in patients with breast cancer and healthy controls.Meanwhile,the chemokine receptor CCR6 expression on peripheral blood CD3＋ T-lymphocytes from patients and controls was analyzed by flow cytometry.Results The serum levels of CCL20 in CCR6＋ patients were significantly higher than those in CCR6-patients and controls（P〈0.01）.There was no statistical difference in the expression of CCR6 on peripheral blood CD3＋ T-lymphocytes among the 3 groups. Conclusions The increase of CCL20 in CCR6＋ patients may play a role in pathogenesis of partial breast cancer.

关 键 词：CCL20 CCR6 乳腺癌 

分 类 号：Q503[生物学—生物化学]